Meanwhile, the presence of higher levels of PD-L1 within the pre-treatment TME can be used to identify patient subpopulations across a range of cancer types (such as non-small cell lung cancer, bladder, and triple negative breast cancers) more likely to respond to anti-PD1 or anti-PDL1 therapy [32]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.